NDAINTRAVENOUSEMULSION
Approved
Oct 2017
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
2/8 — Basic
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VARUBI (rolapitant hydrochloride) is an intravenous NK1 receptor antagonist emulsion indicated for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic cancer chemotherapy. It works by blocking substance P signaling in the chemoreceptor trigger zone and vomiting center of the brain. The drug is administered as a single IV dose prior to chemotherapy.
Peak6.2 years to LOE
Product is in peak commercial phase with minimal direct competitive pressure, supporting stable account management and institutional sales roles.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on VARUBI positions you in account management and institutional sales roles within oncology, where you will manage relationships with hospital systems and cancer centers administering CINV prophylaxis. This is a stable, mature product with predictable commercial demand but limited growth upside, making it ideal for professionals seeking established territory management rather than launch dynamics.
Key Account Manager
Worked on VARUBI at TerSera Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.